Investment in Equity Securities |
9 Months Ended | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2026 | |||||||||||||||||||||
| Investment in Equity Securities [Abstract] | |||||||||||||||||||||
| INVESTMENT IN EQUITY SECURITIES | NOTE 5 — INVESTMENT IN EQUITY SECURITIES
The Company’s investment in Glucotrack consists of 37,884 shares of Glucotrack common stock received in the merger described in Note 1 and the Company’s right to receive 22,691 shares of Glucotrack Series A preferred stock, each convertible into 100 shares of Glucotrack common stock (in each case before Glucotrack’s 1-for-15 reverse stock split effective August 31, 2026). The securities represent 2.889% of the shares issued to Lokahi’s former holders in the merger, and the Company does not have significant influence over Glucotrack. The investment is measured at fair value under ASC 321, with changes in fair value recognized in continuing operations. The Series A preferred stock had not been issued to the Company as of September 30, 2026 and is measured on an as-converted basis using the quoted price of Glucotrack common stock.
The fair value as of September 30, 2026 is based on Glucotrack’s closing price of $1.64 per share on that date and comprises $4,142 for the common stock and $248,088 for the Series A preferred stock on an as-converted basis. |
||||||||||||||||||||